Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 69.21 KRW | 1298.18% |
| 2022 | 4.95 KRW | -97.15% |
| 2021 | 173.74 KRW | -55.01% |
| 2020 | 386.19 KRW | 3.07% |
| 2019 | 374.67 KRW | 481.06% |
| 2018 | 64.48 KRW | -43.44% |
| 2017 | 114.00 KRW | 185.0% |
| 2016 | 40.00 KRW | 125.16% |
| 2015 | -159.00 KRW | 49.36% |
| 2014 | -314.00 KRW | 40.64% |
| 2013 | -529.00 KRW | -569.87% |
| 2012 | -78.97 KRW | 80.71% |
| 2011 | -409.48 KRW | -6924.67% |
| 2010 | 6.00 KRW | -64.71% |
| 2009 | 17.00 KRW | -50.0% |
| 2008 | 34.00 KRW | 213.33% |
| 2007 | -30.00 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -6.37 KRW | 88.72% |
| 2024 Q2 | -65.57 KRW | -929.36% |
| 2024 Q3 | 4.25 KRW | 106.48% |
| 2023 Q3 | 6.29 KRW | -95.64% |
| 2023 Q4 | -56.48 KRW | -997.93% |
| 2023 Q2 | 144.14 KRW | 682.85% |
| 2023 Q1 | -24.73 KRW | -288.23% |
| 2023 FY | - KRW | 1298.18% |
| 2022 Q1 | -1.62 KRW | 91.36% |
| 2022 Q3 | 29.41 KRW | 2034.87% |
| 2022 Q4 | -6.37 KRW | -121.66% |
| 2022 FY | - KRW | -97.15% |
| 2022 Q2 | -1.52 KRW | 6.17% |
| 2021 Q1 | 88.00 KRW | -28.25% |
| 2021 Q3 | 40.00 KRW | -37.5% |
| 2021 Q4 | -18.76 KRW | -146.9% |
| 2021 Q2 | 64.00 KRW | -27.27% |
| 2021 FY | - KRW | -55.01% |
| 2020 FY | - KRW | 3.07% |
| 2020 Q2 | 115.00 KRW | 51.32% |
| 2020 Q3 | 73.00 KRW | -36.52% |
| 2020 Q1 | 76.00 KRW | -37.54% |
| 2020 Q4 | 122.65 KRW | 68.01% |
| 2019 FY | - KRW | 481.06% |
| 2019 Q2 | 82.00 KRW | 28.13% |
| 2019 Q3 | 107.00 KRW | 30.49% |
| 2019 Q4 | 121.67 KRW | 13.71% |
| 2019 Q1 | 64.00 KRW | 222.75% |
| 2018 Q2 | 53.00 KRW | 278.57% |
| 2018 FY | - KRW | -43.44% |
| 2018 Q4 | -52.14 KRW | -204.28% |
| 2018 Q3 | 50.00 KRW | -5.66% |
| 2018 Q1 | 14.00 KRW | -76.38% |
| 2017 Q1 | -8.00 KRW | 31.57% |
| 2017 Q4 | 59.27 KRW | 11.83% |
| 2017 FY | - KRW | 185.0% |
| 2017 Q2 | 10.00 KRW | 225.0% |
| 2017 Q3 | 53.00 KRW | 430.0% |
| 2016 Q4 | -11.69 KRW | -20.89% |
| 2016 FY | - KRW | 125.16% |
| 2016 Q1 | 33.00 KRW | 132.93% |
| 2016 Q2 | 25.00 KRW | -24.24% |
| 2016 Q3 | -9.67 KRW | -138.68% |
| 2015 Q4 | -100.22 KRW | -75.82% |
| 2015 Q2 | -1.00 KRW | -112.5% |
| 2015 Q3 | -57.00 KRW | -5600.0% |
| 2015 Q1 | 8.00 KRW | 102.32% |
| 2015 FY | - KRW | 49.36% |
| 2014 Q3 | 6.00 KRW | 0.0% |
| 2014 FY | - KRW | 40.64% |
| 2014 Q1 | 13.00 KRW | 104.14% |
| 2014 Q4 | -345.43 KRW | -5857.17% |
| 2014 Q2 | 6.00 KRW | -53.85% |
| 2013 FY | - KRW | -569.87% |
| 2013 Q4 | -314.04 KRW | -145.34% |
| 2013 Q3 | -128.00 KRW | -228.21% |
| 2013 Q2 | -39.00 KRW | 20.41% |
| 2013 Q1 | -49.00 KRW | -50.21% |
| 2012 Q2 | -49.00 KRW | -243.86% |
| 2012 FY | - KRW | 80.71% |
| 2012 Q4 | -32.62 KRW | -303.88% |
| 2012 Q3 | 16.00 KRW | 132.65% |
| 2012 Q1 | -14.25 KRW | 91.57% |
| 2011 Q2 | -179.35 KRW | -2399.36% |
| 2011 FY | - KRW | -6924.67% |
| 2011 Q1 | 7.80 KRW | 280.49% |
| 2011 Q4 | -169.00 KRW | 18.36% |
| 2011 Q3 | -207.00 KRW | -15.42% |
| 2010 Q1 | 2.00 KRW | -92.23% |
| 2010 FY | - KRW | -64.71% |
| 2010 Q4 | 2.05 KRW | 2.5% |
| 2010 Q3 | 2.00 KRW | 0.0% |
| 2010 Q2 | 2.00 KRW | 0.0% |
| 2009 Q2 | 2.00 KRW | 455.56% |
| 2009 Q1 | 0.36 KRW | -97.97% |
| 2009 Q3 | 2.00 KRW | 0.0% |
| 2009 Q4 | 25.75 KRW | 1187.5% |
| 2009 FY | - KRW | -50.0% |
| 2008 Q3 | 0.12 KRW | 101.0% |
| 2008 Q4 | 17.72 KRW | 14666.67% |
| 2008 FY | - KRW | 213.33% |
| 2008 Q1 | 28.00 KRW | 36.99% |
| 2008 Q2 | -12.00 KRW | -142.86% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | -2.00 KRW | 94.93% |
| 2007 Q3 | -17.09 KRW | -754.5% |
| 2007 Q1 | -39.46 KRW | 0.0% |
| 2007 Q4 | 20.44 KRW | 219.6% |